The mRNA vaccine from the U.S. manufacturer joins vaccines from AstraZeneca, Pfizer-BioNTech and Johnson & Johnson in receiving the WHO’s emergency use listing. Similar approvals for China’s Sinopharm and Sinovac vaccines are expected in the coming days and weeks, WHO has said.
The greenlight for Moderna’s vaccine, announced late Friday, took many months because of delays WHO faced in getting data from the manufacturer.
Many countries without their own advanced medical regulatory and assessment offices rely on the WHO listing to decide whether to use vaccines. U.N. children’s agency UNICEF also uses the listing to deploy vaccines in an emergency like the pandemic.
The announcement isn’t likely to have an immediate impact on supplies of Moderna’s vaccine for the developing world. The company struck supply agreements with many rich countries, which have already received millions of doses.
In a statement Friday, CEO Stephane Bancel said Moderna was “actively participating in discussions with multilateral organizations, such as COVAX, to help protect populations around the world.”
He’s referring to a U.N.-backed program to ship COVID-19 vaccines to many low- and middle-income countries.
Japanese Health Minister Norihisa Tamura confirmed on Friday that the first doses of Moderna’s vaccine, expected to be approved in May, had arrived in Japan.
If Moderna’s vaccine is approved, it would the second COVID-19 vaccine to approved for use in Japan.
Japan officially approved Pfizer’s COVID-19 vaccine in February this year as it steps up efforts to tame a third wave of infections in the run-up to the Summer Olympic Games.
Reuters contributed to the report.